Bruno SÃ©gui

List of Publications by Year
in descending order

77 papers	2,820 citations	172386 29 h-index	189801 50 g-index
81 all docs	81 docs citations	81 times ranked	4369 citing authors

#	Article	IF	Citations
1	Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial. Clinical Cancer Research, 2021, 27, 1037-1047.	3.2	55
2	Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Antiâ€"PD-1 Therapy Efficacy. Cancer Immunology Research, 2021, 9, 568-582.	1.6	30
3	Combining TNF blockade with immune checkpoint inhibitors in patients with cancer. Nature Reviews Rheumatology, 2021, 17, 577-577.	3.5	4
4	Thrombospondin-1 Silencing Improves Lymphocyte Infiltration in Tumors and Response to Anti-PD-1 in Triple-Negative Breast Cancer. Cancers, 2021, 13, 4059.	1.7	8
5	Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives. Cancers, 2020, 12, 3147.	1.7	31
6	New Insights into the Role of Sphingolipid Metabolism in Melanoma. Cells, 2020, 9, 1967.	1.8	15
7	Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1. Nature Communications, 2020, 11, 437.	5.8	89
8	The TNF Paradox in Cancer Progression and Immunotherapy. Frontiers in Immunology, 2019, 10, 1818.	2.2	198
9	Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma. Frontiers in Pharmacology, 2019, 10, 443.	1.6	22
10	Anti-TNF, a magic bullet in cancer immunotherapy?. , 2019, 7, 303.		21
11	IL13-Mediated Dectin-1 and Mannose Receptor Overexpression Promotes Macrophage Antitumor Activities through Recognition of Sialylated Tumor Cells. Cancer Immunology Research, 2019, 7, 321-334.	1.6	18
12	Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas. Molecular Cancer Therapeutics, 2019, 18, 289-300.	1.9	25
13	Morniga-G, a T/Tn-Specific Lectin, Induces Leukemic Cell Death via Caspase and DR5 Receptor-Dependent Pathways. International Journal of Molecular Sciences, 2019, 20, 230.	1.8	12
14	S1P: the elixir of life for naive T cells. Cellular and Molecular Immunology, 2018, 15, 657-659.	4.8	7
15	Method to Measure Sphingomyelin Synthase Activity Changes in Response to CD95L. Methods in Molecular Biology, 2017, 1557, 207-212.	0.4	5
16	Liquid Chromatographyâ€"High Resolution Mass Spectrometry Method to Study Sphingolipid Metabolism Changes in Response to CD95L. Methods in Molecular Biology, 2017, 1557, 213-217.	0.4	6
17	TNFÎ± blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nature Communications, 2017, 8, 2256.	5.8	284
18	Role of Sphingolipids in Death Receptor Signalling. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 229-245.	0.1	0

#	Article	IF	Citations
19	Glucosylceramidases and malignancies in mammals. Biochimie, 2016, 125, 267-280.	1.3	36
20	Targeting TNF alpha as a novel strategy to enhance CD8⁺T cell-dependent immune response in melanoma?. OncoImmunology, 2016, 5, e1068495.	2.1	12
21	Downregulation of sphingosine kinase-1 induces protective tumor immunity by promoting M1 macrophage response in melanoma. Oncotarget, 2016, 7, 71873-71886.	0.8	35
22	Sphingolipids modulate the epithelialâ€“mesenchymal transition in cancer. Cell Death Discovery, 2015, 1, 15001.	2.0	16
23	Monogenic neurological disorders of sphingolipid metabolism. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 1040-1051.	1.2	25
24	Human genetic disorders of sphingolipid biosynthesis. Journal of Inherited Metabolic Disease, 2015, 38, 65-76.	1.7	29
25	Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasma membrane fluidity and cancer cell motility. Oncogene, 2015, 34, 996-1005.	2.6	77
26	Blocking Tumor Necrosis Factor Î± Enhances CD8 T-cellâ€“Dependent Immunity in Experimental Melanoma. Cancer Research, 2015, 75, 2619-2628.	0.4	81
27	Basics of Sphingolipid Metabolism and Signalling. , 2015, , 1-20.		4
28	TNF-R1, an immune checkpoint in melanoma?. Genes and Cancer, 2015, 6, 369-370.	0.6	4
29	Chemotherapy with ceramide in TNBC. Oncoscience, 2015, 2, 817-818.	0.9	1
30	Dual role of sphingosine kinase-1 in promoting the differentiation of dermal fibroblasts and the dissemination of melanoma cells. Oncogene, 2014, 33, 3364-3373.	2.6	48
31	The pro-inflammatory action of tumour necrosis factor-Î± in non-alcoholic steatohepatitis is independent of the NSMAF gene product. Digestive and Liver Disease, 2013, 45, 147-154.	0.4	6
32	Genetic Disorders of Simple Sphingolipid Metabolism. Handbook of Experimental Pharmacology, 2013, , 127-152.	0.9	3
33	The nonlysosomal Î²â€glucosidase GBA2 promotes endoplasmic reticulum stress and impairs tumorigenicity of human melanoma cells. FASEB Journal, 2013, 27, 489-498.	0.2	39
34	Phosphorylation of Serine Palmitoyltransferase Long Chain-1 (SPTLC1) on Tyrosine 164 Inhibits Its Activity and Promotes Cell Survival. Journal of Biological Chemistry, 2013, 288, 17190-17201.	1.6	21
35	The Tricyclodecan-9-yl-xanthogenate D609 Triggers Ceramide Increase and Enhances FasL-Induced Caspase-Dependent and -Independent Cell Death in T Lymphocytes. International Journal of Molecular Sciences, 2012, 13, 8834-8852.	1.8	14
36	Ordering of ceramide formation and caspase-9 activation in CD95L-induced Jurkat leukemia T cell apoptosis. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2012, 1821, 684-693.	1.2	11

#	Article	IF	Citations
37	Is active acid sphingomyelinase required for the antiproliferative response to rituximab?. Blood, 2011, 117, 3695-3696.	0.6	5
38	Morniga G: A Plant Lectin as an Endocytic Ligand for Photosensitizer Molecule Targeting Toward Tumorâ€Associated T/Tn Antigens. Photochemistry and Photobiology, 2011, 87, 370-377.	1.3	18
39	CD95 triggers Orai1-mediated localized Ca²⁺entry, regulates recruitment of protein kinase C (PKC) Î²2, and prevents death-inducing signaling complex formation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 19072-19077.	3.3	52
40	Targeting of T/Tn Antigens with a Plant Lectin to Kill Human Leukemia Cells by Photochemotherapy. PLoS ONE, 2011, 6, e23315.	1.1	17
41	Regulation of Death and Growth Signals at the Plasma Membrane by Sphingomyelin Synthesis: Implications for Hematological Malignancies. Recent Patents on Anti-Cancer Drug Discovery, 2011, 6, 324-333.	0.8	10
42	Caspase-mediated inhibition of sphingomyelin synthesis is involved in FasL-triggered cell death. Cell Death and Differentiation, 2010, 17, 642-654.	5.0	49
43	Redistribution of CD95 into the Lipid Rafts to Treat Cancer Cells?. Recent Patents on Anti-Cancer Drug Discovery, 2010, 5, 22-28.	0.8	14
44	Caspase-10-Dependent Cell Death in Fas/CD95 Signalling Is Not Abrogated by Caspase Inhibitor zVAD-fmk. PLoS ONE, 2010, 5, e13638.	1.1	16
45	Apolipoprotein Eâ€"Deficient Mice Develop an Antiâ€"Chlamydophila pneumoniaeT Helper 2 Response and Resist Vascular Infection. Journal of Infectious Diseases, 2010, 202, 782-790.	1.9	11
46	R31: Ã‰tude du rÃ1e des sphingomyÃ©line synthases (SMS) dans la signalisation cytotoxique induite par les ligands des rÃ©cepteurs de mort (FasL et TRAIL). Bulletin Du Cancer, 2010, 97, S28.	0.6	0
47	FAN (factor associated with neutral sphingomyelinase activation), a moonlighting protein in TNF-R1 signaling. Journal of Leukocyte Biology, 2010, 88, 897-903.	1.5	17
48	IL-6 Deficiency Attenuates Murine Diet-Induced Non-Alcoholic Steatohepatitis. PLoS ONE, 2009, 4, e7929.	1.1	75
49	FAN Stimulates TNFÎ±-Induced Gene Expression, Leukocyte Recruitment, and Humoral Response. Journal of Immunology, 2009, 183, 5369-5378.	0.4	18
50	Two structurally identical mannose-specific jacalin-related lectins display different effects on human T lymphocyte activation and cell death. Journal of Leukocyte Biology, 2009, 86, 103-114.	1.5	22
51	Interleukin-6 Deficiency Fails to Prevent Chronic Rejection After Aortic Allografts in Apolipoprotein Eâ€"Deficient Mice. Journal of Heart and Lung Transplantation, 2009, 28, 85-92.	0.3	5
52	Cleavage and Cytoplasmic Relocalization of Histone Deacetylase 3 Are Important for Apoptosis Progression. Molecular and Cellular Biology, 2007, 27, 554-567.	1.1	62
53	OPA1 cleavage depends on decreased mitochondrial ATP level and bivalent metals. Experimental Cell Research, 2007, 313, 3800-3808.	1.2	90
54	Sphingolipids as modulators of cancer cell death: Potential therapeutic targets. Biochimica Et Biophysica Acta - Biomembranes, 2006, 1758, 2104-2120.	1.4	116

#	Article	IF	Citations
55	Multiple Human Mesenteric Arterial Grafts From the Same Donor to Study Human Chronic Vascular Rejection in Humanized SCID/Beige Mice. Journal of Heart and Lung Transplantation, 2006, 25, 675-682.	0.3	17
56	Caspase-dependent and -independent cell death of Jurkat human leukemia cells induced by novel synthetic ceramide analogs. Leukemia, 2006, 20, 392-399.	3.3	45
57	Chlamydia pneumoniaeAlters Mildly Oxidized Lowâ€Density Lipoproteinâ€“Induced Cell Death in Human Endothelial Cells, Leading to Necrosis Rather Than Apoptosis. Journal of Infectious Diseases, 2006, 193, 136-145.	1.9	29
58	Caspase-10 Triggers Bid Cleavage and Caspase Cascade Activation in FasL-induced Apoptosis. Journal of Biological Chemistry, 2005, 280, 19836-19842.	1.6	94
59	Engraftment of human T, B and NK cells in CB.17 SCID/beige mice by transfer of human spleen cells. Transplant Immunology, 2005, 15, 157-164.	0.6	17
60	Role of FAN in Tumor Necrosis Factor-Î± and Lipopolysaccharide-induced Interleukin-6 Secretion and Lethality in d-Galactosamine-sensitized Mice. Journal of Biological Chemistry, 2004, 279, 18648-18655.	1.6	32
61	Expression of membraneâ€bound and soluble FasL in Fasâ€•and FADDâ€dependent T lymphocyte apoptosis induced by mildly oxidized LDL. FASEB Journal, 2004, 18, 122-124.	0.2	22
62	Phosphorylation of a Distinct Structural Form of Phosphatidylinositol Transfer Protein Î± at Ser166 by Protein Kinase C Disrupts Receptor-mediated Phospholipase C Signaling by Inhibiting Delivery of Phosphatidylinositol to Membranes. Journal of Biological Chemistry, 2004, 279, 47159-47171.	1.6	21
63	Voies de signalisation de lâ€™apoptose mÃ©diÃ©es par les sphingolipides. SociÃ©tÃ© De Biologie Journal, 2003, 197, 217-221.	0.3	5
64	Sphingolipid signalling: molecular basis and role in TNF-Î±-induced cell death. Expert Reviews in Molecular Medicine, 2002, 4, 1-15.	1.6	17
65	Phosphatidylinositol transfer protein Î² displays minimal sphingomyelin transfer activity and is not required for biosynthesis and trafficking of sphingomyelin. Biochemical Journal, 2002, 366, 23-34.	1.7	37
66	Current thoughts on the phosphatidylinositol transfer protein family. FEBS Letters, 2002, 531, 74-80.	1.3	73
67	Evidence for the Lack of Involvement of Sphingomyelin Hydrolysis in the Tumor Necrosis Factor-Induced Secretion of Nerve Growth Factor in Primary Astrocyte Cultures. Journal of Neurochemistry, 2002, 71, 498-505.	2.1	10
68	Ceramide in apoptosis: a revisited role. Neurochemical Research, 2002, 27, 601-607.	1.6	58
69	Ceramide in Apoptosis:. Molecular Biology Intelligence Unit, 2002, , 73-80.	0.2	1
70	Un rÃ´le pour la protÃ©ine FAN (factor associated with neutral sphingomyelinase activation) dans la signalisation de lâ€™apoptose. Medecine/Sciences, 2001, 17, 1210-1213.	0.0	0
71	The CB₁ Cannabinoid Receptor of Astrocytes Is Coupled to Sphingomyelin Hydrolysis through the Adaptor Protein Fan. Molecular Pharmacology, 2001, 59, 955-959.	1.0	98
72	Lysosomal sphingomyelinase is not solicited for apoptosis signaling. FASEB Journal, 2001, 15, 297-299.	0.2	63

#	Article	IF	Citations
73	Involvement of FAN in TNF-induced apoptosis. Journal of Clinical Investigation, 2001, 108, 143-151.	3.9	91
74	Stressâ€induced apoptosis is not mediated by endolysosomal ceramide. FASEB Journal, 2000, 14, 36-47.	0.2	63
75	CD40 Signals Apoptosis through FAN-regulated Activation of the Sphingomyelin-Ceramide Pathway. Journal of Biological Chemistry, 1999, 274, 37251-37258.	1.6	64
76	Retrovirus-Mediated Correction of the Metabolic Defect in Cultured Farber Disease Cells. Human Gene Therapy, 1999, 10, 1321-1329.	1.4	30
77	Sphingomyelin-degrading pathways in human cells. Chemistry and Physics of Lipids, 1999, 102, 167-178.	1.5	31